PROCEPT BioRobotics
PROCEPT BioRobotics (AquaBeam): >50,000 procedures (historical; strong growth). Publicly traded; 2025 revenue ~$308–309M; 2026 guidance $390–410M (27–33% growth), procedure growth 39–48%. Positive EBITDA target 2027. Oncology/urology (BPH; prostate tissue ablation; cancer potential)
RobotToday Initiative
Robotics needs a service framework.
RSF defines a common language for robot service capability, lifecycle operations, certification pathways, and service-provider networks.
Is PROCEPT BioRobotics Corporation (PRCT) A Good Stock To Buy Now?
PROCEPT BioRobotics Corporation (PRCT) has garnered attention as a potential investment opportunity, with a bullish thesis highlighted on the r/ValueInvesting forum by user mrmrmrj. As of June 17, 2026, PRCT shares were trading at $20.91, reflecting significant growth in the surgical robotics sector. The company has seen its revenues quadruple since 2022, indicating strong early-stage economies of scale akin to its larger competitor, Intuitive Surgical (ISRG). Despite PRCT's impressive growth, trading at approximately 4.5 times sales presents a notable valuation gap compared to ISRG's historical performance, which experienced a volatile sales multiple range during a similar developmental phase. Analysts suggest that if PRCT can replicate ISRG's trajectory, the stock could appreciate by around 150% over the next three years, driven by revenue compounding and market re-rating. However, near-term sentiment is mixed, as management has guided revenues slightly below expectations, although still reflecting a robust 30% year-over-year growth. Looking ahead, 2027 revenue projections indicate a significant acceleration that may not yet be fully recognized by analysts, potentially leading to an upside surprise. While PRCT is not among the top 40 most popular stocks among hedge funds, interest has increased, with 28 hedge fund portfolios holding shares as of the end of the first quarter. Despite the risks associated with PRCT, some analysts believe that certain AI stocks may offer greater short-term returns.
RobotToday Weekly Industry Briefing: January 4 - january 9, 2026
Global robotics shifts from CES 2026: humanoid commercialization accelerates, industrial AI deepens, labor tensions rise, and robotics markets recalibrate.
Leave a comment